Monoclonal Antibodies in Cancer — Are They Immunotherapy?

A monoclonal antibody is a laboratory-made copy of a single immune protein, designed to lock onto one specific target. It is given as an infusion. What it does after it locks on depends entirely on what it locked onto — a marker on a cancer cell, a growth signal the cancer depends on, or a brake on your own immune cells.

Your body already makes antibodies. They are Y-shaped proteins that recognise one shape and stick to it. Monoclonal simply means every antibody in the vial is identical, grown from a single parent cell line, so every dose behaves the same way. That is a manufacturing description. It tells you how the medicine was made. It tells you nothing about what it does inside you.

In cancer care, antibodies are put to five broadly different jobs. One antibody may flag a cancer cell so your immune cells destroy it. Another may sit on a growth-factor receptor and block the signal the cell depends on. A third may carry a chemotherapy payload and deliver it to cells that display the target. A fourth may block a checkpoint on your own T cells so they stay active. A fifth may grip an immune cell with one arm and a cancer cell with the other, so the two are held together.

Those five jobs are why one word cannot answer the question in the title. The format is shared. The mechanism is not. Everything else on this page follows from that single distinction.

The categories are not policed perfectly, and careful sources disagree at the edges. NCCN, ASCO and ESMO patient material tends to describe the mechanism rather than lean on the label, which is the safer habit to copy. No row above says anything about how well any group works, and none is offered here as better than another.

Because four separate things push in the same direction. The medicines share a naming suffix. They are all introduced as not chemotherapy. Antibodies are themselves immune proteins, so any antibody sounds like immunotherapy. And billing paperwork in India often prints the word immunotherapy against any antibody infusion.

• The shared -mab suffix — the naming convention is about molecular format, not about what the medicine does. It gives two very different treatments the same family resemblance on a prescription slip.
• Everything gets grouped as not chemotherapy — families are told the treatment is not chemotherapy, and that single negative becomes the category. Two medicines can both be not chemotherapy and still act on entirely different systems.
• Antibodies are immune proteins by nature — it is a reasonable assumption that a medicine made of an immune protein must be an immune treatment. It is still the wrong assumption. What matters is the target it was built for.
• Paperwork uses one word for many mechanisms — bills, pre-authorisation forms and scheme applications may all say immunotherapy for any antibody infusion. Ask your treating team which class it actually is, and ask for that to be written on your treatment plan so the paperwork and the mechanism agree.
• Translation flattens the difference — in everyday Telugu or Hindi conversation, both are described as the injection that boosts immunity. Neither class does that. One releases a brake on an immune response you already have. The other blocks a signal the cancer depends on.

This matters more than a vocabulary argument, and here is the reason. Families read the word on the bill, search for it, and then apply the wrong side-effect list to their own treatment. A daughter watching for immune inflammation of the thyroid or gut, while her father is actually on a growth-signal-blocking antibody, is watching the wrong window — and not watching the one that applies to him.

Yes, in three practical ways: which side effects you watch for, how you are monitored between cycles, and what the words on your bill and insurance form actually mean. It does not change whether the treatment suits you. That was decided on your cancer type, stage and test results, not on the label.

• The side-effect windows are different — checkpoint-blocking antibodies can inflame healthy organs such as the skin, gut, thyroid, liver or lungs, and can do so weeks or months after starting. Tumour-directed antibodies more often cause infusion reactions and effects tied to the target being blocked. Ask for the written list that matches your class, not a general one.
• The monitoring schedule is different — which blood tests are repeated, at what interval, and when response is assessed all follow the class. Assessment on immune-directed treatment is deliberately delayed, because the effect builds over weeks rather than hours. Response-assessment PET-CT is coordinated at partner imaging centres, not owned by CION.
• What counts as urgent is different — with immune-directed antibodies, some new symptoms are treated as urgent because immune inflammation can escalate quickly. Your team will ask about small symptoms at every visit for exactly this reason.
• The paperwork may not match the mechanism — ask which class is being given, and have it written down before pre-authorisation is filed. Any cost figure you are quoted is indicative only, as of August 2026, and should be given to you in writing rather than over the phone.
• Eligibility runs target by target — a test showing one target is present says nothing about any other. Most cancer patients in India are not candidates for immune checkpoint treatment, and being suitable for a tumour-directed antibody does not make you suitable for it, or the reverse.

• Not an immunity booster — no antibody medicine raises general immunity. An immunity drip, vitamin infusion or immunity injection sold outside oncology acts on nothing described on this page. Tell your treating team before taking anything of that kind, so it can be checked against your plan and your blood tests.
• Not a cancer vaccine — a vaccine tries to teach your immune system to recognise a target for itself. An antibody is the finished recognition protein, made outside the body and handed to you ready-formed. Cancer Vaccines: What They Are and What They Are Not sets out that difference properly.
• Not the only kind of immunotherapy — the oldest immunotherapy still in routine use is a live bacterial preparation placed into the bladder, and it is not an antibody at all. BCG Therapy for Bladder Cancer: The Oldest Immunotherapy explains how that one works.
• Not CAR-T or cell therapy — CAR-T collects a patient's own immune cells, re-engineers them outside the body and returns them. It is a separate class with separate risks, used in a small number of specific blood cancers. CION does not provide CAR-T or any cell therapy; our role is orientation and referral only.
• Not always single-target — an antibody can be built to hold two targets at once, gripping an immune cell with one arm and a cancer cell with the other. Bispecific Antibodies and T-Cell Engagers covers that group, which sits firmly on the immunotherapy side of the table above.

1. 1

   Ask for the class in writing

   Ask directly: is this an immune checkpoint antibody, a growth-signal-blocking antibody, an antibody carrying a chemotherapy payload, or a bispecific antibody? Ask for the answer to be written on your treatment plan, not only said in the room.

2. 2

   Look at which test triggered it

   If the decision followed a biomarker result such as PD-L1 expression, MSI or dMMR status, or tumour mutational burden, you are almost certainly in the immune-directed group. If it followed a receptor or marker test on the tumour tissue itself, you are in the tumour-directed group.

3. 3

   Ask for the side-effect list that matches that class

   Two lists, please. What is common and manageable, and what means call now. Keep the second list where the family can see it, and give a copy to whoever is at home with you between cycles.

4. 4

   Ask what the monitoring schedule is

   Which blood tests, at what interval, and when the first response assessment is planned. At CION these infusions are given as day care, and response-assessment PET-CT is coordinated at partner imaging centres rather than done in-house.

5. 5

   Check what the paperwork says

   Compare the class you were told with the wording on the bill, the pre-authorisation form and any scheme application. If they disagree, have it corrected before the claim is filed rather than after it is rejected.

• Cancer Vaccines: What They Are and What They Are Not — the other immune treatment that gets confused with antibodies, and the one where expectations most often run ahead of the evidence.
• Bispecific Antibodies and T-Cell Engagers — the antibody group that is unambiguously immunotherapy, and how holding two targets at once changes the monitoring.
• BCG Therapy for Bladder Cancer: The Oldest Immunotherapy — useful proof that immunotherapy is not a new category and does not have to involve an antibody at all.
• Immunotherapy at CION Cancer Clinics — the hub page: biomarker testing, day-care administration, monitoring and support in one place.

This page explains classes of medicine from a scientific standpoint and is general information, not a treatment recommendation and not a substitute for consultation. No product or brand is named or endorsed here, and no class is presented as performing better than another. Immunotherapy is administered as day care at CION centres; response-assessment PET-CT is coordinated at partner imaging centres. CION does not provide CAR-T or cell therapy. Only your oncologist, reviewing your complete case, can say whether any of this applies to you.

Every family wants to know what is going into the drip

Asking which class of medicine is being given, and what it acts on, is not doubting your doctor. It is how you become useful to your own treatment. Our team takes the time to explain it.